Reality Check on Hereditary Angioedema
Market access for hereditary angioedema (HAE) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 57% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In December 2020, the FDA approved BioCryst Pharmaceuticals, Inc.’s Orladeyo (berotralstat) for prophylaxis to prevent hereditary angioedema attacks in people at least 12 years old. It is the first oral treatment approved for this use
- Key Findings: Health plans don't differentiate coverage among provider-administered
products, and access to HAE products is not limited at the brand level. However, increased competition is expected as more prophylactic therapies enter the market
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.